The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium.
circulating tumor cells
long-term survival
primary epithelial ovarian cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
21
04
2021
revised:
20
05
2021
accepted:
22
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
We previously reported the prognostic impact of circulating tumor cells (CTCs) in a multicenter study on minimal residual disease in primary ovarian cancer. With additional follow-up data, we evaluated the combined CTC approach (CTCs Blood samples taken at baseline and six months after adjuvant treatment (follow-up) were assessed by quantitative PCR (qPCR) measuring PPIC transcripts and immunofluorescent staining (IF). A positive result with either IF or qPCR was classified as CTC The concordance of IF and qPCR was 65% at baseline and 83% after treatment. Results showed that 50.5% of the baseline and 29.5% of the follow-up samples were CTC The two-sided analytical approach revealed CTC subpopulations associated with ovarian cancer progression and may illuminate a potential treatment-related shift in molecular phenotypes. That approach can identify patients who have elevated risk of recurrence and death due to ovarian cancer and who may require risk-adapted treatment strategies.
Identifiants
pubmed: 34073412
pii: cancers13112613
doi: 10.3390/cancers13112613
pmc: PMC8198007
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Transl Res. 2016 Sep;175:92-102.e2
pubmed: 27083386
Cancers (Basel). 2020 Aug 05;12(8):
pubmed: 32764409
Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):996-999
pubmed: 30967418
Obstet Gynecol. 2012 Sep;120(3):612-8
pubmed: 22914471
BMC Cancer. 2010 Dec 03;10:666
pubmed: 21129172
Cancer. 1993 Dec 15;72(12):3641-7
pubmed: 8252480
Gynecol Oncol. 2018 Jan;148(1):204-212
pubmed: 29128106
Gynecol Oncol. 2014 Feb;132(2):334-42
pubmed: 24368280
Obstet Gynecol. 2015 Sep;126(3):491-497
pubmed: 26244529
Oncol Lett. 2021 May;21(5):422
pubmed: 33850563
Gynecol Oncol. 2013 Jan;128(1):15-21
pubmed: 23017820
Int J Mol Sci. 2020 Jul 07;21(13):
pubmed: 32646060
Cells. 2019 Aug 13;8(8):
pubmed: 31412616
Biochem J. 1999 Jul 1;341 ( Pt 1):127-32
pubmed: 10377253
Cytometry A. 2007 Mar;71(3):154-62
pubmed: 17200956
Br J Cancer. 1996 May;73(10):1233-6
pubmed: 8630284
Acta Oncol. 2010 Jun;49(5):725-36
pubmed: 20491528
BMC Cancer. 2014 Jul 15;14:514
pubmed: 25023626
BMC Cancer. 2013 Sep 17;13:422
pubmed: 24044611
Clin Chem. 1996 Nov;42(11):1881-2
pubmed: 8906098
Cancer Cell. 2014 Jul 14;26(1):77-91
pubmed: 25026212
Int J Mol Sci. 2016 Oct 28;17(11):
pubmed: 27801851
Int J Gynecol Cancer. 2021 May;31(5):713-720
pubmed: 33563640
J Clin Oncol. 2000 Apr;18(7):1432-9
pubmed: 10735890
Oncotarget. 2017 Nov 16;8(63):106415-106428
pubmed: 29290959
Breast Cancer Res. 2013 Mar 07;15(2):R20
pubmed: 23497487
Int J Gynecol Cancer. 2013 Feb;23(2):268-75
pubmed: 23358178
Phys Ther. 2005 Mar;85(3):257-68
pubmed: 15733050
Br J Cancer. 2010 Jan 19;102(2):276-84
pubmed: 19953098
Mol Oncol. 2015 Apr;9(4):920-32
pubmed: 25655581
Mol Oncol. 2016 Aug;10(7):1030-42
pubmed: 27157930
Clin Chem. 2018 Feb;64(2):297-306
pubmed: 29122836
Oncotarget. 2017 Nov 28;9(1):812-823
pubmed: 29416657
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Clin Chem Lab Med. 2018 Jan 26;56(2):186-197
pubmed: 28753534
Oncotarget. 2017 Jul 25;8(30):48820-48831
pubmed: 28415744